ArticleScientific reports2025
Optical signature of retinal Tau fibrillation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multimodal Retinal Imaging for the Detection of Early Alzheimer's Disease: Combining Biochemical, Structural, and Vascular Biomarkers.Bioengineering (Basel, Switzerland) · 2026Article
- From Food Additives to Neurodegeneration: The Emerging Role of Polyphosphates in Tauopathies.ACS chemical neuroscience · 2026Review
- Non-invasive screening of alzheimer's disease via label-free tri-spectral retinal imaging.Scientific reports · 2026Article
- Short-chain polyphosphates induce tau fibrillation and neurotoxicity in human iPSC-derived retinal neurons.Cell death & disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Fibrillated Tau proteins are believed to be a signature of Alzheimer's disease (AD) and may be potentially employed as a biosensor for AD early detection. Several studies revealed the presence of Tau accumulation and aggregation in the retina, similar to that observed in the brains of individuals with AD. These retinal changes can be non-invasively visualised through AD-related scores derived from reflectance measurements of the patient fundus. However, a direct link with the optical properties of fibrillated protein clusters is still lacking. Here, we present a new optical technique which measures the scattering optical properties of protein fibrils. Our experimental findings show that the scattering intensity of Tau has a wavelength dependence correlated to their size. The optical signal qualitatively replicates the spectral signature observed in human AD patient retinas. Our paper shows that the Tau protein spectral signature is compatible with the distinctive spectral signature of the AD, further confirming that retinal investigation is a promising tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.